Elsevier

Nutrition

Volume 27, Issue 2, February 2011, Pages 206-213
Nutrition

Applied nutritional investigation
Green tea minimally affects biomarkers of inflammation in obese subjects with metabolic syndrome

https://doi.org/10.1016/j.nut.2010.01.015Get rights and content

Abstract

Objective

Green tea (Camellia sinensis) has shown to exert cardioprotective benefits in observational studies. The objective of this clinical trial was to assess the effects of green tea on features of metabolic syndrome and inflammation in obese subjects.

Methods

We conducted a randomized controlled trial in obese subjects with metabolic syndrome. Thirty-five subjects [(mean ± SE) age 42.5 ± 1.7 y, body mass index 36.1 ± 1.3 kg/m2] completed the 8-wk study and were randomly assigned to receive green tea (4 cups/d), green tea extract (2 capsules and 4 cups water/d), or no treatment (4 cups water/d). Both the beverage and extract groups had similar dosing of epigallocatechin-3-gallate, the active green tea polyphenol. Fasting blood samples were collected at screening, 4 and 8 wk of the study.

Results

Green tea beverage or extract supplementation did not significantly alter features of metabolic syndrome or biomarkers of inflammation including adiponectin, C-reactive protein, interleukin-6, interleukin-1β, soluble vascular cell adhesion molecule-1, soluble intercellular adhesion molecule-1, leptin, or leptin:adiponectin ratio. However, both green tea beverage and extracts significantly reduced plasma serum amyloid alpha versus no treatment (P < 0.005).

Conclusion

This study suggests that the daily consumption of green tea beverage or extracts for 8 wk was well tolerated but did not affect the features of metabolic syndrome. However, green tea significantly reduced plasma serum amyloid alpha, an independent cardiovascular disease risk factor, in obese subjects with metabolic syndrome.

Introduction

A growing body of evidence indicates the role of green tea or its bioactive polyphenol, epigallocatechin gallate (EGCG), in significantly ameliorating features of metabolic syndrome, and subsequent risks for type 2 diabetes mellitus and cardiovascular disease (CVD) [1], [2], [3]. Metabolic syndrome, a constellation of several risk factors, including abdominal adiposity, hypertension, dyslipidemia [high triglycerides, low high-density lipoproteins (HDL)], and impaired fasting glucose, has also been associated with chronic inflammation, insulin resistance, and endothelial dysfunction [4], [5]. Habitual consumption of green tea (Camellia sinensis), a popular beverage used in traditional Chinese medicine, has been associated with decreased risks for obesity [6], diabetes [7], [8], hypertension [9], dyslipidemia [10], [11], and CVD mortality [12], [13], [14] in several epidemiological studies. In selected clinical trials, green tea supplementation has been shown to significantly improve features of metabolic syndrome, such as decreased abdominal adiposity indicated by waist circumference in obese subjects [15], [16], [17], reduced blood glucose and hemoglobin A1C in prediabetic or diabetic patients [18], [19], improved postprandial lipid responses in subjects with mild hypertriglyceridemia [20], and increased flow-mediated dilation in smokers or subjects with endothelial dysfunction [21], [22]. However, these epidemiologic and clinical studies have been mostly conducted in populations in Asian countries with habitual green tea consumption. Also, in some trials outcomes are significant versus baseline but not control group, or are possibly confounded by the habitual caffeine intake by the subjects, or caffeine content in green tea. Thus, these limited human studies showing positive effects of green tea in metabolic syndrome emphasize the need for further controlled intervention trials using decaffeinated green tea in populations with salient features of metabolic syndrome and CVD risk factors.

Clinical trials have reported mixed results on the effects of green tea on biomarkers of inflammation, which is associated with metabolic syndrome and CVD. In an uncontrolled study in male smokers, green tea consumption (600 mL/d) for 4 wk was shown to decrease P-selectin levels, suggesting a decrease in risk factors of atherosclerosis in these subjects [23]. In contrast, in a randomized controlled study, green tea intervention (900 mL green tea or 3.6 g green tea polyphenols) for 4 wk showed no effects on inflammatory markers such as C-reactive protein (CRP), interleukin-6 (IL-6), interleukin- 1β (IL-1β), or tumor necrosis factor-α in healthy smokers [24]. In a postprandial study, green tea intake (6 g) versus controls improved endothelial function, but had no effects on biomarkers of inflammation in healthy individuals [25]. Studies in subjects with borderline diabetes or diabetes have shown no significant effects of green tea consumption (456 g green tea catechins for 2 mo or 900 mL of green tea for 4 wk) on markers of inflammation [18], [26]. Thus, based on these results, anti-inflammatory effects of green tea supplementation need further investigation in subjects with metabolic syndrome in controlled long-term intervention trials.

Several mechanistic studies using animal models of obesity, metabolic syndrome, and CVD also provide data substantiating the anti-obesity [27], [28], anti-diabetic [29], [30], anti-hypertensive [31], [32], anti-hyperlipidemic [33], [34], and anti-inflammatory [35], [36] effects of green tea. Ramadan et al. [34] have reported the effects of a 28-d supplementation of green tea aqueous extracts in significantly alleviating hyperglycemia, dyslipidemia, and impaired liver function in male Wistar albino rats fed a cholesterol-rich diet. Ramesh et al. [35] have shown anti-inflammatory effects of intraperitoneal administration of EGCG (100 mg/kg body weight) in significantly reducing serum CRP levels and hematologic markers of inflammation in rats fed an atherogenic diet versus the untreated group. Oral administration of EGCG (100 mg/kg body weight) in aged male Wistar albino rats fed a high-fat diet was also shown to significantly decrease CRP and tumor necrosis factor-α versus the unsupplemented group [36]. Thus, these animal studies show the benefits of green tea extracts or EGCG treatment in reversing high-fat diet induced inflammation and glucose and lipid abnormalities associated with metabolic syndrome. These potential benefits of green tea need to be confirmed in clinical trials, especially in US populations with increasing prevalence of obesity and metabolic syndrome [37].

Thus, the objective of our study was to test whether daily consumption of green tea beverage (4 cups/d) or extracts (2 capsules/d and 4 cups water/d) over a period of 8 wk would affect biomarkers of inflammation and features of metabolic syndrome versus age- and gender-matched no treatment (4 cups water/d) group, thereby lowering CVD risk factors in the US population with metabolic syndrome.

Section snippets

Subjects

Forty-one subjects with metabolic syndrome were recruited by flyers and e-mail advertisements at the General Clinical Research Center (GCRC) at University of Oklahoma Health Sciences Center. Subjects were included in the study if they had three of five features of metabolic syndrome as defined by the National Cholesterol education Program, Adult Treatment Panel III guidelines [38]. Participants were excluded from the trial if they were under 21 y of age, had a preexisting condition (e.g.,

Results

Forty-one individuals were recruited for the study. Two people withdrew due to relocation and personal reasons, and four were withdrawn on account of starting cholesterol- (one) and glucose-lowering (one) medications during the study, and for smoking (two). Thus, a total of 35 subjects completed the study with a mean age of 42.5 ± 1.7 y and a mean body mass index of 36.1 ± 1.3 kg/m2 at the screening visit. No significant differences were noted in baseline characteristics except for total and

Discussion

To our knowledge, this is the first study investigating the effects of decaffeinated green tea supplementation on biomarkers of inflammation and features of metabolic syndrome in obese population in the US. Our study results show that green tea beverage or extract supplementation selectively lowers plasma SAA versus the no treatment group. However, green tea intervention did not affect inflammatory markers including CRP, IL-6, IL-1β, sVCAM-1, sICAM-1, adiponectin, and leptin or features of

Conclusion

Green tea beverage or extract supplementation in obese subjects with metabolic syndrome for 8 wk was well tolerated and reduced circulating SAA versus no treatment group, but did not affect other biomarkers of inflammation (CRP, IL-6, IL-1β, sICAM-1, sVCAM-1), adiponectin, and features of metabolic syndrome. Thus, green tea may be included as part of a comprehensive strategy involving diet, exercise, and specific dietary supplementations aimed at reversing inflammation, endothelial dysfunction,

Acknowledgments

This work was supported by the University of Oklahoma Health Sciences Center General Clinical Research Center Grant M01-RR14467, National Center for Research Resources, National Institutes of Health. This work was also supported by a Core Research grant from College of Human Environmental Sciences, Oklahoma State University.

References (81)

  • X.M. Nguyen et al.

    Changes in inflammatory biomarkers across weight classes in a representative US population: a link between obesity and inflammation

    J Gastrointest Surg

    (2009)
  • G.A. Coetzee et al.

    Serum amyloid A-containing human high density lipoprotein 3. Density, size, and apolipoprotein composition

    J Biol Chem

    (1986)
  • A. Boynton et al.

    Associations between healthy eating patterns and immune function or inflammation in overweight or obese postmenopausal women

    Am J Clin Nutr

    (2007)
  • G.W. Varilek et al.

    Green tea polyphenol extract attenuates inflammation in interleukin-2-deficient mice, a model of autoimmunity

    J Nutr

    (2001)
  • S. Auclair et al.

    Catechin reduces atherosclerotic lesion development in apo E-deficient mice: a transcriptomic study

    Atherosclerosis

    (2009)
  • M.P. Nantz et al.

    Standardized capule of Camellia sinensis lowers cardiovascular risk factors in a randomized, double-blind, placebo-controlled study

    Nutrition

    (2009)
  • D.J. Jenkins et al.

    Effects of high- and low-isoflavone (phytoestrogen) soy foods on inflammatory biomarkers and proinflammatory cytokines in middle-aged men and women

    Metabolism

    (2002)
  • D.A. Morrow et al.

    Serum amyloid A predicts early mortality in acute coronary syndromes: A TIMI 11A substudy

    J Am Coll Cardiol

    (2000)
  • O.K. Chun et al.

    Serum C-reactive protein concentrations are inversely associated with dietary flavonoid intake in U.S. adults

    J Nutr

    (2008)
  • R. di Giuseppe et al.

    Regular consumption of dark chocolate is associated with low serum concentrations of C-reactive protein in a healthy Italian population

    J Nutr

    (2008)
  • M.E. Widlansky et al.

    Effects of black tea consumption on plasma catechins and markers of oxidative stress and inflammation in patients with coronary artery disease

    Free Radic Biol Med

    (2005)
  • N.T. Mulvihill et al.

    Evidence of prolonged inflammation in unstable angina and non-Q wave myocardial infarction

    J Am Coll Cardiol

    (2000)
  • A. Ludwig et al.

    The tea flavonoid epigallocatechin-3-gallate reduces cytokine-induced VCAM-1 expression and monocyte adhesion to endothelial cells

    Biochem Biophys Res Commun

    (2004)
  • F.M. Gonçalves et al.

    Increased circulating levels of matrix metalloproteinase (MMP)-8, MMP-9, and pro-inflammatory markers in patients with metabolic syndrome

    Clin Chim Acta

    (2009)
  • K.K. Koh et al.

    Comparison of effects of losartan, irbesartan, and candesartan on flow-mediated brachial artery dilation and on inflammatory and thrombolytic markers in patients with systemic hypertension

    Am J Cardiol

    (2004)
  • A. Dvoráková-Lorenzová et al.

    The decrease in C-reactive protein concentration after diet and physical activity induced weight reduction is associated with changes in plasma lipids, but not interleukin-6 or adiponectin

    Metabolism

    (2006)
  • S. Wolfram

    Effects of green tea and EGCG on cardiovascular and metabolic health

    J Am Coll Nutr

    (2007)
  • J.S. Rana et al.

    Cardiovascular metabolic syndrome–-an interplay of, obesity, inflammation, diabetes and coronary heart disease

    Diabetes Obes Metab

    (2007)
  • S. Buscemi et al.

    Glycaemic variability and inflammation in subjects with metabolic syndrome

    Acta Diabetol

    (2009)
  • C.H. Wu et al.

    Relatioship among habitual tea consumption, percent body fat, and body fat distribution

    Obes Res

    (2003)
  • H. Iso et al.

    The relationship between green tea and total caffeine intake and risk for self reported type 2 diabetes among Japanese adults

    Ann Intern Med

    (2006)
  • T. Yamaji et al.

    Coffee consumption and glucose tolerance status in middle-aged Japanese men

    Diabetologia

    (2004)
  • Y.C. Yang et al.

    The protective effect of habitual tea consumption on hypertension

    Arch Intern Med

    (2004)
  • K. Imai et al.

    Cross sectional study of effects of drinking green tea on cardiovascular and liver diseases

    BMJ

    (1995)
  • S. Kuriyama et al.

    Green tea consumption and mortality due to cardiovascular disease, cancer, and all causes in Japan: the Ohsaki study

    JAMA

    (2006)
  • H.D. Sesso et al.

    Coffee and tea intake and the risk of myocardial infarction

    Am J Epidemiol

    (1999)
  • T. Shimazu et al.

    Dietary patterns and cardiovascular disease mortality in Japan: a prospective cohort study

    Int J Epidemiol

    (2007)
  • M.S. Westerterp-Plantenga et al.

    Body weight loss and weight maintenance in relation to habitual caffeine intake and green tea supplementation

    Obes Res

    (2005)
  • Y. Fukino et al.

    Randomized controlled trial for an effect of green tea consumption on insulin resistance and inflammation markers

    J Nutr Sci Vitaminol (Tokyo)

    (2005)
  • Y. Fukino et al.

    Randomized controlled trial for an effect of green tea-extract powder supplementation on glucose abnormalities

    Eur J Clin Nutr

    (2008)
  • Cited by (145)

    • Tannins

      2023, Pharmacognosy: Fundamentals, Applications, and Strategies, Second Edition
    • Cardiovascular disease

      2023, Industrial Application of Functional Foods, Ingredients and Nutraceuticals: Extraction, Processing and Formulation of Bioactive Compounds
    • A polyphenol-rich dietary pattern improves intestinal permeability, evaluated as serum zonulin levels, in older subjects: The MaPLE randomised controlled trial

      2021, Clinical Nutrition
      Citation Excerpt :

      We may speculate that the different results could be ascribable to the type of target population under study i.e. the older subjects and/or the sample size and the extent and duration of the intervention. The same could be hypothesized for the lack of effect of the dietary intervention on ICAM-1 and VCAM-1 levels and similar results are present in literature [39–41]. As previously reported for inflammatory markers, we found a large inter-individual variability for the vascular markers and this may have precluded the observation of significant effects of the treatment versus control diet.

    View all citing articles on Scopus

    This study was presented in part at the 49th Annual meeting of the American College of Nutrition and won the Best Poster Award in 2008 (http://www.americancollegeofnutrition.org/Default.aspx?tabid=121).

    Conflicts of interest: None.

    View full text